[HTML][HTML] Red blood cell alloimmunisation in transfusion-dependent thalassaemia: a systematic review

M Franchini, GL Forni, G Marano, M Cruciani… - Blood …, 2019 - ncbi.nlm.nih.gov
Background Chronic red blood cell transfusion is the first-line treatment for severe forms of
thalassaemia. This therapy is, however, hampered by a number of adverse effects, including …

Glycophorins and the MNS blood group system: a narrative review

GH Lopez, CA Hyland, RL Flower - Annals of Blood, 2021 - eprints.qut.edu.au
The MNS blood group system, International Society of Blood Transfusion (ISBT) 002, is
second after the ABO system. GYPA and GYPB genes encode MNS blood group antigens …

People with blood disorders can be more vulnerable during COVID-19 pandemic: A hypothesis paper

D Aydemir, NN Ulusu - Transfusion and Apheresis Science, 2021 - Elsevier
The world has been encountered with COVID-19 pandemic since at the beginning of 2020
and the number of infected people by COVID-19 is increasing every day. Despite various …

Predictors of autoimmune hemolytic anemia in beta-thalassemia patients with underlying red blood cells autoantibodies

MB Khaled, M Ouederni, N Sahli, N Dhouib… - Blood Cells, Molecules …, 2019 - Elsevier
In beta-thalassemia patients, erythrocyte autoantibodies can remain silent or lead to
Autoimmune Hemolytic Anemia (AIHA). The aim of this study was to identify predictors of …

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia

HM Al-Kuraishy, AI Al-Gareeb - Asian journal of transfusion …, 2017 - journals.lww.com
RESULTS: In deferoxamine-treated patients, serum ferritin levels were high
(8160.33±233.75 ng/dL) compared to deferasirox-treated patients (3000.62±188.23 ng/dL; …

Red cell alloimmunization in multi-transfused, oncology patients: Risks and management

S Mangwana, A Kacker, N Simon - Global Journal of Transfusion …, 2019 - journals.lww.com
Materials and Methods: A study was undertaken to know risk of alloimmunization in multi-
transfused, oncology patients and its management in a tertiary care oncology hospital over 3 …

Red blood cell alloimmunization among transfusion-dependent thalassemia major patients in Northeastern Iran

L Mobasheri, T Chahkandi, A Talebpour… - Asian Journal of …, 2023 - journals.lww.com
BACKGROUND: Thalassemia is one of the most common congenital hemoglobinopathies
globally. Regular red blood cell (RBC) transfusion is of paramount importance in the …

[PDF][PDF] Alloimmunization against Rh and Kell blood groups antigens is the main obstacle for blood transfusion in transfusion dependent thalassemia patients in Iran

A Dorgalaleh, MS Gholami, M Shokuhiyan… - Int J Case Rep …, 2017 - academia.edu
Thalassemia is the most common inherited singlegene disorder, causes by decrease or
absence of α-globin or β-globin chain production. The disorder commonly inherited in …

Frequency and specificity of Red blood cell alloantibodies in multitransfused Egyptian patients with hematological and nonhematological malignancies

RMA El Fetouh, GM Abd Elmoniem, RM Allam… - … and Apheresis Science, 2020 - Elsevier
Background Repeated blood transfusions can result in the production of alloantibodies
against one or more red blood cell (RBC) antigens, which can complicate future …

Genotyping of blood groups in alloimmunized patients with β-thalassemia major by T-ARMS-PCR and multiplex-aso-pcr

MS Gholami, M Shahidi, S Tabibian, M Naderi… - … and Apheresis Science, 2021 - Elsevier
Introduction Beta-thalassemia major is a severe hemolytic anemia requiring life-long blood
transfusion. Planned random donor blood transfusion is associated with alloimmunization …